Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)

Baumann M, Groessmann N

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
The FDA granted pembrolizumab accelerated approval and the breakthrough status for the new indication non-small cell lung cancer (NSCLC) in October 2015, based on KEYNOTE-001. This phase Ib-study delivered evidence supporting the efficacy and tolerability of the therapy in previously treated patients with advanced and PD-L1 expressing NSCLC. KEYNOTE-010, a randomised, open-label phase III trial reports efficacy and adverse events (AEs) of pembrolizumab (in two different dosages) in comparison to docetaxel. Generalisability of the results could be compromised due to the stringent inclusion criteria of ECOG-performance 0/1 and the relatively young median age (63 years) of the studied population. Open questions remain regarding the combination with other therapeutics and the comparison with other targeted therapies such as nivolumab. In addition, the benefit for patients with EGFR mutation needs to be further examined. Data for quality of life are still missing. Overall, KEYNOTE-010 reported a significantly improved OS with fewer side-effects compared to the chemotherapeutic docetaxel. Evidence is however still relatively scarce when it comes to patient related outcomes as well as long term effects, and to identify those patients who benefit most from pembrolizumab remains a challenge.

Project page URL
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie

Final publication URL
http://eprints.hta.lbg.ac.at/1086/1/DSD__HSO_ Nr.58.pdf

Additional data URL
http://eprints.hta.lbg.ac.at/1086/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms

Language Published
English

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Health Technology Assessment (HTA) database
Copyright © 2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99

AccessionNumber
32016000583

Date abstract record published
29/03/2016